Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Craig Nelson

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 4, 2018
Screening for Executive Dysfunction in Late-Life Depression: Utility of Trail Making Test and Self-Report MeasuresDavid Bickford, Ruth T Morin, Dan Catalinotto, et al.
The American Journal of Psychiatry|May 25, 2018
Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-AnalysisJ Craig Nelson, David Bickford, Kevin Delucchi, et al.
Current Medical Research and Opinion|December 23, 2003
Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing homeSteven P Roose, J Craig Nelson, Carl Salzman, et al.
Current Medical Research and Opinion|April 16, 2013
Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressantsJ Craig Nelson, Qianyi Zhang, Katarina Kelin, et al.
Psychiatric Services (Washington, D.C.)|January 15, 2016
Mental Health Service Use Across the Life Course Among Adults With Psychiatric Disorders and Prior Suicidal BehaviorAmy L Byers, Amy X Lai, Patricia Arean, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 10, 2013
Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placeboMichael Robinson, Tina Myers Oakes, Joel Raskin, et al.
Biological Psychiatry|June 26, 2007
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsGeorge I Papakostas, Michael E Thase, Maurizio Fava, et al.
Biological Psychiatry|January 28, 2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized studyJ Craig Nelson, Carolyn M Mazure, Peter I Jatlow, et al.
International Journal of Geriatric Psychiatry|April 21, 2007
Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?J Craig Nelson, Karen Holden, Steven Roose, et al.
Journal of Affective Disorders|August 1, 2014
Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placeboSeetal Dodd, Michael Berk, Katarina Kelin, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 4, 2018
Screening for Executive Dysfunction in Late-Life Depression: Utility of Trail Making Test and Self-Report MeasuresDavid Bickford, Ruth T Morin, Dan Catalinotto, et al.
The American Journal of Psychiatry|May 25, 2018
Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-AnalysisJ Craig Nelson, David Bickford, Kevin Delucchi, et al.
Current Medical Research and Opinion|December 23, 2003
Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing homeSteven P Roose, J Craig Nelson, Carl Salzman, et al.
Current Medical Research and Opinion|April 16, 2013
Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressantsJ Craig Nelson, Qianyi Zhang, Katarina Kelin, et al.
Psychiatric Services (Washington, D.C.)|January 15, 2016
Mental Health Service Use Across the Life Course Among Adults With Psychiatric Disorders and Prior Suicidal BehaviorAmy L Byers, Amy X Lai, Patricia Arean, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 10, 2013
Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placeboMichael Robinson, Tina Myers Oakes, Joel Raskin, et al.
Biological Psychiatry|June 26, 2007
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsGeorge I Papakostas, Michael E Thase, Maurizio Fava, et al.
Biological Psychiatry|January 28, 2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized studyJ Craig Nelson, Carolyn M Mazure, Peter I Jatlow, et al.
International Journal of Geriatric Psychiatry|April 21, 2007
Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?J Craig Nelson, Karen Holden, Steven Roose, et al.
Journal of Affective Disorders|August 1, 2014
Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placeboSeetal Dodd, Michael Berk, Katarina Kelin, et al.
Pageof 9